Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04542291 · ClinicalTrials.gov registry record · Phase 1
Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition
A Phase 1 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04542291 is a Phase 1 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 15 participants.
The verdict
NCT04542291, a Phase 1 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this patient population. The investigators also hypothesize that dapagliflozin will be efficacious as an adjunct to front-line chemotherapy assessed by decreased tumor markers mediated by its pleiotropic metabolic effects.
Interventions
- DRUG Dapagliflozin
- DEVICE BIOSENSE meters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2022-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04542291
The ClinicalTrials.gov registry entry for NCT04542291 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT04542291 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04542291 about?
NCT04542291 is a clinical study titled "Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition". This is a first-in-human, pilot study of the feasibility and safety of dapagliflozin (in addition to standard of care treatment) for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The primary hypothesis is that dapagliflozin is well-tolerated and safe to use in this pati...
What is the current status of trial NCT04542291?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-02-25. Estimated completion is 2022-01-19.
What interventions are being tested in trial NCT04542291?
The interventions under investigation include: Dapagliflozin (DRUG), BIOSENSE meters (DEVICE).
Who is sponsoring clinical trial NCT04542291?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.